Drugs / 11C-JMJ-129
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06874205 | Apr 2025 → Feb 2028 expected | — | National Institute of Mental Health (NIMH) | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 11C-JMJ-129 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06874205 ↗ |
| Modality | Diagnostic / imaging agent | “11C-JMJ-129 is a new radiotracer (a radioactive substance that highlights parts of the body during imaging scans)” NCT06874205 ↗ |
| Route | Intravenous | “Injected IV followed by PET scanning” NCT06874205 ↗ |
| Target | PDE4D | “attach only to PDE4D” NCT06874205 ↗ |